Concentra Group Holdings Parent, Inc. (CON) AI Stock Analysis

Concentra Group Holdings Parent, Inc. provides occupational health services in the United States through three segments: Occupational Health centers, Onsite health clinics, and Other business. It offers workers compensation, employer, and consumer health services, alongside employer-sponsored primary care at workplaces, mobile health, and episodic specialty testing. The company also operates Concentra Telemed for work-related injuries, Concentra Pharmacy for distributing repackaged medications, and Concentra Medical Compliance Administration for managing substance abuse testing programs. In addition, it provides injury care, urgent care, physical examinations, vaccinations, clinical testing, drug and alcohol screenings, and consultative workplace hazard services.

Revenue grew from $1.73B in FY2021 to $2.16B in FY2025, representing a four-year revenue CAGR of 5.7%. Annual revenue declined 0.4% in FY2022 before expanding 6.6% in FY2023, 3.4% in FY2024, and 13.9% in FY2025. Gross margin increased from 24.7% in FY2021 to 28.3% in FY2025, while operating margin moved from 15.6% to 15.4%. Net income was $166.4M in FY2025 with a net margin of 7.7%, compared to $208.9M and 12.1% in FY2021. For the trailing twelve months ended June 30, 2026, revenue totaled $2.29B. In the latest quarter, quarterly revenue grew 10.0% year-over-year, and quarterly earnings grew 47.0% year-over-year.

As of June 30, 2026, Concentra held $158.0M in cash and short-term investments against total debt of $2.14B, resulting in net debt of $1.99B. Total assets stood at $3.01B, shareholders' equity was $477.1M, and the current ratio was 1.38. Debt-to-equity was 4.49. In FY2025, operating cash flow reached $279.4M and free cash flow was $197.1M. Capital allocation in FY2025 included $82.3M for capital expenditures, $22.4M for share buybacks, and $32.1M for dividends paid.

Concentra trades at a trailing P/E of 24.9x and a forward P/E of 18.0x, compared to medians of 24.6x and 17.3x for its US-listed Healthcare peers. Its enterprise value to EBITDA sits at 14.1x versus the peer median of 12.0x, while its price-to-sales ratio of 2.1x is below the peer median of 4.1x. The company has an enterprise value of $6.42B and a market cap of $4.91B. Over the past year, the stock returned 95.6%, compared to a 16.8% return for the S&P 500.

Concentra pays a quarterly dividend with an annual forward payout of $0.25, translating to a dividend yield of 0.65%. The company has paid dividends for 3 consecutive years. Its payout ratio stands at 15.8%, and the last ex-dividend date was August 20, 2026. Dividends paid in FY2025 totaled $32.1M.

Wall Street coverage includes 7 Strong Buy and 2 Buy ratings, with no Hold, Sell, or Strong Sell ratings. The mean price target is $41.67, representing an 8.1% upside from the last close of $38.54. Analysts beat EPS estimates in all 4 of the last 4 quarters. Consensus estimates project FY2026 revenue of $2.35B and EPS of $1.65, reflecting 20.5% EPS growth. The next earnings date is November 5, 2026.

This page is an AI-written research summary of Concentra Group Holdings Parent, Inc. (CON). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CON income statement, CON balance sheet, CON key metrics, CON analyst forecast, CON chart. See the CON stock overview for the latest quote and news.